aceSerum albumin is associated with immune-related hypothyroidism and treatment continuity in non-small cell lung cancer
Background Immune checkpoint inhibitors (ICIs) are a standard treatment for advanced non-small cell lung cancer (NSCLC), but clinically practical predictors of immune-related adverse events (irAEs) and treatment continuity remain limited. Methods We conducted a retrospective cohort study using two nationwide Japanese administrative claims databases: Medical Data Vision (MDV) and the Japan Medical Data Center (JMDC). Patients with advanced NSCLC treated with ICIs were identified. Those with available thyroid func…
In patients with advanced NSCLC receiving first-line immune checkpoint inhibitors, higher baseline serum albumin predicted by machine learning models was associated with significantly prolonged time to next treatment or death.
Retrospective design using administrative claims databases limits clinical detail and generalizability beyond Japanese advanced NSCLC cohorts included.
Evidence
- Peer-reviewedInternational Journal of Clinical Oncology2026-10-03
How should this claim be treated?
Truvace Impact Record TRV-2026-1285, v1: “Serum albumin is associated with immune-related hypothyroidism and treatment continuity in non-small cell lung cancer.” Truvace, 2026-10-05. /record/TRV-2026-1285 (accessed at citation time). sha256 9e769358ed6d3386…
Calibration history
Every change to this record since certification, in the open. None yet — the reading has held since it entered the record.
Certified into the record
How to verify without trusting this page
Fetch the canonical text of any version from /api/record/TRV-2026-1285 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.